ITB Med

Executive Summary

ITB Med is a Swedish private biotech company developing a novel therapy aimed at eliminating the lifelong need for immunosuppression after organ transplantation. Founded in 2015 and based in Stockholm, the company addresses a critical unmet need: current immunosuppressive regimens reduce graft rejection but cause significant toxicity, increased infection risk, and long-term organ damage. ITB Med's approach seeks to induce immune tolerance, potentially allowing transplant recipients to maintain their graft without continuous immunosuppression. This could dramatically improve quality of life, reduce healthcare costs, and extend graft survival. While the company has not disclosed its specific technology platform or clinical stage, its focus aligns with a major trend in transplantation medicine toward tolerance induction. The company remains private with no disclosed funding or valuation, suggesting early-stage development with limited public data.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Phase 1 Trial40% success
• Q3 2026Preclinical Proof-of-Concept Data Publication60% success
• 2027Strategic Partnership or Licensing Deal25% success